George M. Lasezkay - Jan 18, 2024 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
CLSD
Transactions as of
Jan 18, 2024
Transactions value $
-$22,860
Form type
4
Date filed
1/19/2024, 06:26 PM
Previous filing
Sep 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Sale -$22.9K -18K -3.71% $1.27 467K Jan 19, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLSD Employee Stock Option (right to buy) Award $0 +440K $0.00 440K Jan 18, 2024 Common Stock 440K $1.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 One-fourth of the shares underlying this option vest on January 18, 2025 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.